EUVIMEDEUVIMED entdecken
Crossref

HLA‐A*11:01 and HLA‐C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups

Yuanzhi Lv, Kangzhi Chen iD, Mengchuan Luo, Yuzhen Ouyang, Kailin Li, Zhaohui Luo iD, Huan Yang iD

HLA · 2026-04 · 107 (4)

DOI: 10.1111/tan.70697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HLA, online erschienen am 02.04.2026. Verfasst von Yuanzhi Lv und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Tacrolimus, Myasthenia Gravis, HLA-C Antigens, HLA-A Antigens. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tacrolimus (TAC) is recommended for the patients with drug tolerance or respond poorly to other conventional immunosuppressants in myasthenia gravis (MG), but its effectiveness is influenced by dose and genetic polymorphism. Studies suggest that HLA polymorphisms are significantly associated with susceptibility to MG, but the relationship between HLA and TAC efficacy in MG has not been explored. In this paper, we investigated the correlation between TAC therapeutic efficacy and HLA in different MG subgroups. HLA‐C*03 was associated with a better response to TAC in patients with early‐onset MG, generalized MG, and those with a high concentration of TAC. While HLA‐A*11:01 showed poor responsiveness to TAC in generalized MG. Furthermore, computational docking was used to demonstrate the binding situation of HLA‐A with the TAC binding protein FKBP1A. It showed that HLA‐A*11:01 had a higher binding strength with FKBP1A than HLA‐C*03 , indicating that the combination of different types of HLA and FKBP1A may be one of the reasons affecting its therapeutic efficacy. This study highlights the influence of HLA on the efficacy of TAC among different MG subgroups, providing clues for precise treatment of MG with TAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TacrolimusMyasthenia GravisHLA-C AntigensHLA-A AntigensTacrolimus Binding Protein 1AImmunosuppressive AgentsHumansFemaleProtein BindingMolecular Docking SimulationMaleAdultMiddle AgedTacrolimus Binding Proteins

Stichwörter der Autor:innen

HLAclinical efficacymyasthenia gravistacrolimus

Substanzen

TacrolimusHLA-C AntigensHLA-A AntigensTacrolimus Binding Protein 1AFKBP1A protein, humanImmunosuppressive AgentsTacrolimus Binding Proteins

Autor:innen und Institutionen

  • Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Clinical Research Center for Epileptic Disease of Hunan Province, Central South University, Changsha, China.
  • Department of Neurology, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, China.
  • Research Center for Neuroimmune and Neuromuscular Disorders, Xiangya Hospital, Central South University, Changsha, China.

ORCID-Profile: Kangzhi Chen, Zhaohui Luo, Huan Yang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lv, Y., Chen, K., Luo, M., Ouyang, Y., Li, K., Luo, Z., & Yang, H. (2026). HLA‐A*11:01 and HLA‐C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups. HLA, 107(4). https://doi.org/10.1111/tan.70697

Vancouver

Lv Y, Chen K, Luo M, Ouyang Y, Li K, Luo Z, et al. HLA‐A*11:01 and HLA‐C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups. HLA. 2026;107(4). doi:10.1111/tan.70697

BibTeX
@article{Lv2026,
  author = {Lv, Yuanzhi and Chen, Kangzhi and Luo, Mengchuan and Ouyang, Yuzhen and Li, Kailin and Luo, Zhaohui and Yang, Huan},
  title = {HLA‐A*11:01 and HLA‐C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups},
  journal = {HLA},
  year = {2026},
  volume = {107},
  number = {4},
  doi = {10.1111/tan.70697}
}
Kostenlos starten →